Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles

• Main Authors: Michel Boutin, Pamela Lavoie, Iskren Menkovic, Amanda Toupin, Mona Abaoui, Maha Elidrissi-Elawad, Marie-Françoise Arthus, Carole Fortier, Claudia Ménard, Bruno Maranda, Daniel G. Bichet, Christiane Auray-Blais
• Format: Article
• Language: English
• Published: MDPI AG 2020-08-01
• Series: International Journal of Molecular Sciences
• Subjects: Fabry disease; diurnal variation; globotriaosylceramide; globotriaosylsphingosine; mass spectrometry; glycosphingolipids
• Online Access: https://www.mdpi.com/1422-0067/21/17/6114
• ISSN: 1661-6596; 1422-0067

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the <i>GLA</i> gene encoding the α-galactosidase A enzyme. This enzyme cleaves the last sugar unit of glycosphingolipids, including globotriaosylceramide (Gb₃), globotriaosylsphingosine (lyso-Gb₃), and galabiosylceramide (Ga₂). Enzyme impairment leads to substrate accumulation in different organs, vascular endothelia, and biological fluids. Enzyme replacement therapy (ERT) is a commonly used treatment. Urinary analysis of Gb₃ isoforms (different fatty acid moieties), as well as lyso-Gb₃ and its analogues, is a reliable way to monitor treatment. These analogues correspond to lyso-Gb₃ with chemical modifications on the sphingosine moiety (−C₂H₄, −C₂H₄+O, −H₂, −H₂+O, +O, +H₂O₂, and +H₂O₃). The effects of sample collection time on urinary biomarker levels between ERT cycles were not previously documented. The main objective of this project was to analyze the aforementioned biomarkers in urine samples from seven Fabry disease patients (three treated males, three treated females, and one ERT-naïve male) collected twice a day (morning and evening) for 42 days (three ERT cycles). Except for one participant, our results show that the biomarker levels were generally more elevated in the evening. However, there was less variability in samples collected in the morning. No cyclic variations in biomarker levels were observed between ERT infusions.